Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-25

Protalix BioTherapeutics (PLX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,166,934
Dror Bashan total, FY2025
1st
CEO pay percentile vs peers
CEO-to-median pay ratio
80.93%
Say-on-pay support, latest vote
Companies that benchmark against PLX
No companies currently name PLX as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Dror Bashan$401,836$279,491$190,015$169,017$0$0$126,575$1,166,934
President and Chief Executive Officer
Eyal Rubin240,576181,208183,39331,45200195,832832,461
Senior Vice President and Chief Financial Officer
Yaron Naos232,78490,11577,80479,8260095,240575,769
Senior Vice President, Chief Operating Officer
Gilad Mamlok133,91900229,7290041,577405,225
Senior Vice President and Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Dror Bashan$1,166,934
Eyal Rubin832,461
Yaron Naos575,769
Gilad Mamlok405,225

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Dror BashanRSU178,750$321,750
Yaron NaosRSU69,753125,555
Dror BashanOption140,6251.03
Dror BashanOption311,6671.64
Gilad MamlokOption548,1581.45
Yaron NaosOption63,7501.03
Yaron NaosOption58,3331.1
Yaron NaosOption45,8331.64
05

Incentive-plan design — the Compensation Discussion & Analysis

The primary goals of the Compensation Committee are to attract and retain the most talented and dedicated executives possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives, and to align executives’ incentives with stockholder value creation.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultant
Clawback policy
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2528,368,6146,683,937197,60280.93%Passed
20252025-06-2616,440,4497,488,809384,20268.7%Passed
20242024-06-2717,038,3949,884,021410,79063.29%Passed
20222022-06-3016,953,3263,466,524218,59083.02%Passed
20202020-06-0714,550,1874,306,979180,01177.16%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2580.93%a
20252025-06-2668.7%b
20242024-06-2763.29%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)
Stock ownership guideline
10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Protalix BioTherapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Protalix BioTherapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Option2025John Rademacher$1,000,000$6,500,050$0$1,665,000$9,266,330
2Stock2025James Hillebrand875,000656,250218,7501,487,5003,380,337
3Protalix BioTherapeutics2025Dror Bashan401,836190,015169,01701,166,934

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Protalix BioTherapeuticsnot disclosednot disclosednot disclosednot disclosed
Option111%PSU 60 · RSU 40NoPearl Meyer
Stock200%PSU 75 · Options 25NoAon's Human Capital Solutions

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Dror BashanDEF 14A2026-04-300001104659-26-053016Section “Executive Compensation”. As printed: 1,166,934. Filing ↗
2Section 01, Eyal RubinDEF 14A2026-04-300001104659-26-053016Section “Executive Compensation”. As printed: 832,461. Filing ↗
3Section 01, Yaron NaosDEF 14A2026-04-300001104659-26-053016Section “Executive Compensation”. As printed: 575,769. Filing ↗
4Section 01, Gilad MamlokDEF 14A2026-04-300001104659-26-053016Section “Executive Compensation”. As printed: 405,225. Filing ↗
5Section 06, 2026 voteForm 8-K2026-06-250001104659-26-077790Item 5.07 · say-on-pay result. As reported: 80.93% (votes for as printed: 28,368,614). Filing ↗
6Section 06, 2025 voteForm 8-K2025-06-260001558370-25-008922Item 5.07 · say-on-pay result. As reported: 68.7% (votes for as printed: 16,440,449). Filing ↗
7Section 06, 2024 voteForm 8-K2024-06-280001558370-24-009567Item 5.07 · say-on-pay result. As reported: 63.29% (votes for as printed: 17,038,394). Filing ↗
8Option, Section 10b CEO totalDEF 14A2026-04-080001140361-26-013825CEO total compensation as printed in Option's own proxy. As printed: 9,266,330. Filing ↗machine: r2 · c25 · span 1114074–1114083
9Stock, Section 10b CEO totalDEF 14A2026-03-120001437749-26-007879CEO total compensation as printed in Stock's own proxy. As printed: 3,380,337. Filing ↗machine: r3 · c32 · span 991255–991264
10Protalix BioTherapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001104659-26-053016CEO total compensation as printed in Protalix BioTherapeutics's own proxy. As printed: 1,166,934. Filing ↗
11Section 10a, Stock reciprocityDEF 14A0001437749-26-007879Stock's most recent proxy was read; its disclosed peer group does not include Protalix BioTherapeutics. Filing ↗
12Section 10a, Option reciprocityDEF 14A0001140361-26-013825Option's most recent proxy was read; its disclosed peer group does not include Protalix BioTherapeutics. Filing ↗